CervoMed's stock soars 400% on promising dementia drug data. See more on insights, potential concerns, and what it means for ...

The clinical-stage company on Monday said that, following "highly encouraging" 16-week extension results from the Phase 2b trial, it believes it has established proof-of-concept for neflamapimod as a ...

Reported positive 16-week results from the extension phase of the Phase 2b RewinD-LB trial of neflamapimod in dementia with Lewy bodies (DLB), ...

“Following the highly encouraging 16-week extension results from our Phase 2b RewinD-LB trial, we believe we have established proof-of-concept for neflamapimod as a potential treatment for DL ...

Reported positive 16-week results from the extension phase of the Phase 2b RewinD-LB trial of neflamapimod in dementia with Lewy bodies (DLB), including improvement on the trial’s primary ...

We recently published a list of 10 Best Short-Term Stocks To Buy Right Now. In this article, we are going to take a look at ...

(MENAFN- GlobeNewsWire - Nasdaq) -Reported positive 16-week results from the extension phase of the Phase 2b RewinD-LB trial of neflamapimod in dementia with Lewy bodies (DLB), including ...

The short percent of float rose after the company announced positive results for its Phase 2b clinical study of Neflamapimod in patients with dementia with Lewy bodies. The company’s price ...

Stock analysts at Roth Capital reduced their Q1 2025 earnings per share estimates for CervoMed in a report issued on Tuesday, ...